No Data
No Data
ProKidney Executive Sells $41,030 in Company Stock
ProKidney Initiated at Buy by Guggenheim
Guggenheim Initiates Coverage On ProKidney With Buy Rating, Announces Price Target of $6
Guggenheim Initiates ProKidney(PROK.US) With Buy Rating, Announces Target Price $6
Buy Rating on ProKidney: Promising Prospects in Chronic Kidney Disease Treatment
ProKidney Drops Phase III CKD Study to Focus on US Market and Save up to $175m
No Data
No Data